IP Library › Patent Application 18949376
Patent Application
App. No. 18/949,376

FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND ONE OR MORE STATINS AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/949,376
Abstract

Disclosed herein are compositions comprising fixed doses of ETC-1002 and one or more statins. Also disclosed herein are methods for using fixed doses of ETC-1002 and one or more statins. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject.

Claims (14)

1 . A method of reducing LDL-C in a subject in need thereof, the method comprising administering to the subject 120 mg or 180 mg ETC-1002 and 20-40 mg rosuvastatin.

2 . The method of claim 1 , wherein the method comprises administering to the subject 120 mg ETC-1002.

3 . The method of claim 1 , wherein the method comprises administering to the subject 180 mg ETC-1002.

4 . The method of claim 2 , wherein the method comprises administering to the subject 20 mg rosuvastatin.

5 . The method of claim 3 , wherein the method comprises administering to the subject 20 mg rosuvastatin.

6 . The method of claim 2 , wherein the method comprises administering to the subject 40 mg rosuvastatin.

7 . The method of claim 3 , wherein the method comprises administering to the subject 40 mg rosuvastatin.

8 . A method of reducing LDL-C in a subject in need thereof, the method comprising administering to the subject 120 mg or 180 mg ETC-1002 and 40-80 mg atorvastatin.

9 . The method of claim 8 , wherein the method comprises administering to the subject 120 mg ETC-1002.

10 . The method of claim 8 , wherein the method comprises administering to the subject 180 mg ETC-1002.

11 . The method of claim 9 , wherein the method comprises administering to the subject 40 mg atorvastatin.

12 . The method of claim 10 , wherein the method comprises administering to the subject 40 mg atorvastatin.

13 . The method of claim 9 , wherein the method comprises administering to the subject 80 mg atorvastatin.

14 . The method of claim 10 , wherein the method comprises administering to the subject 80 mg atorvastatin.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jul 14, 2026
From: GLAS AMERICAS LLC
To: ESPERION THERAPEUTICS INC.
Reel/Frame 075267/0816 →
PATENT SECURITY AGREEMENT Recorded Jul 13, 2026
From: ESPERION THERAPEUTICS, INC.; RESQ PHARMACEUTICALS LLC
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 075952/0812 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2024
From: NEWTON, ROGER SCHOFIELD; ROSENBERG, NOAH LABAN; MACDOUGALL, DIANE ELAINE
To: ESPERION THERAPEUTICS, INC.
Reel/Frame 069612/0153 →
SECURITY INTEREST Recorded Dec 13, 2024
From: ESPERION THERAPEUTICS, INC.
To: GLAS AMERICAS LLC
Reel/Frame 069582/0756 →